Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2017, Vol. 22 ›› Issue (10): 1123-1126.

Previous Articles     Next Articles

Radix tetrastigma hemsleyani flavone suppresses human lung carcinoma A549 cell via proteasome inhibition

ZHONG Liangrui 1, CHEN Hua 1, JING Jing 1, QIAO Hongli 1, WEI Kemin 2, WANG Weidong 3   

  1. 1 TongDe Hospital of Zhejiang Province, Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310012, Zhejiang, China; 2 Zhejiang Academy of Traditional Chinese Medicine, Hangzhou 310007, Zhejiang, China; 3 the Second Hospital of Zhejiang Chinese Medical University, Hangzhou 310007, Zhejiang, China
  • Received:2017-07-31 Revised:2017-10-23 Online:2017-10-26 Published:2017-11-13

Abstract:

AIM: To study the effect of radix tetrastigma hemsleyani flavone (RTHF) on the growth in human lung carcinoma A549 cells as well as its mechanisms. METHODS: A549 cells were treated with the RTHF in different concentrations. The proliferation of A549 cell was detected by MTT assay in vitro. Enzyme proteasome assay was used to detect the activity of proteasome and DUB. Expressions of ubiquitin proteasome pathway associated proteins were detected by Real-time PCR and Western blot. RESULTS: MTT showed that RTHF had obvious anti-proliferation effect on A549 cells in a dose-dependent manner. Enzyme proteasome assay showed that the treatment of activity of proteasome and DUB was significantly lower than the proportion in the control group (P<0.05). Real-time PCR and Western blot showed the protein expression of ub-prs and was up-regulated significantly and that of USP14, UCHL5, POH1 were down- regulated in RTHF group when compared with the control group. CONCLUSION: Radix tetrastigma hemsleyani flavone may inhibit the proliferation of lung cancer A549 cells through the ubiquitin proteasome pathway.

Key words: radix tetrastigma hemsleyani flavone, A549 cell, proliferation inhibition, proteasome

CLC Number: